Analysis Of Income And Expense [Abstract]

ABIONYX Pharma - Filing #2813091

Concept 2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
5 252 EUR
675,000 EUR
Material income and expense [abstract]
Research and development expense
1 107 EUR
3 838 EUR
Finance income (cost)
97,000 EUR
130,000 EUR
Interest expense
- EUR
- EUR
Interest expense on borrowings
- EUR
- EUR
Selling, general and administrative expense [abstract]
Selling, general and administrative expense
3 661 EUR
2 336 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, before tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, before tax, exchange differences on translation of foreign operations
39,000 EUR
39,000 EUR
48,000 EUR
48,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
3 985 EUR
5 759 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.